Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractImmunization with an inactivated virus is one of the strategies currently being tested towards developing a SARS-CoV-2 vaccine. One of the methods used to inactivate viruses is exposure to high doses of ionizing radiation to damage their nucleic acids. While gamma (γ) rays effectively induce lesions in the RNA, envelope proteins are also highly damaged in the process. This in turn may alter their antigenic properties, affecting their capacity to induce an adaptive immune response able to confer effective protection. Here, we modeled the effect of sparsely and densely ionizing radiation on SARS-CoV-2 using the Monte Carlo toolkit Geant4-DNA. With a realistic 3D target virus model, we calculated the expected number of lesions in the spike and membrane proteins, as well as in the viral RNA. Our findings showed that γ rays produced significant spike protein damage, but densely ionizing charged particles induced less membrane damage for the same level of RNA lesions, because a single ion traversal through the nuclear envelope was sufficient to inactivate the virus. We propose that accelerated charged particles produce inactivated viruses with little structural damage to envelope proteins, thereby representing a new and effective tool for developing vaccines against SARS-CoV-2 and other enveloped viruses.
CitationRadiat Res. 2021 Mar 1;195(3):221-229. doi: 10.1667/RADE-20-00241.1.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
PublisherRadiation Research Society
The following license files are associated with this item:
- Creative Commons
- A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
- Authors: Sharma O, Sultan AA, Ding H, Triggle CR
- Issue date: 2020
- A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
- Authors: Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, Vitner EB, Israeli O, Milrot E, Stein D, Cohen-Gihon I, Lazar S, Gutman H, Glinert I, Cherry L, Vagima Y, Lazar S, Weiss S, Ben-Shmuel A, Avraham R, Puni R, Lupu E, Bar-David E, Sittner A, Erez N, Zichel R, Mamroud E, Mazor O, Levy H, Laskar O, Yitzhaki S, Shapira SC, Zvi A, Beth-Din A, Paran N, Israely T
- Issue date: 2020 Dec 16
- DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice.
- Authors: Szurgot I, Hanke L, Sheward DJ, Vidakovics LP, Murrell B, McInerney GM, Liljeström P
- Issue date: 2021 Feb 4
- N-terminally truncated nucleocapsid protein of SARS-CoV-2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS-CoV-2.
- Authors: Yue L, Cao H, Xie T, Long R, Li H, Yang T, Yan M, Xie Z
- Issue date: 2021 Mar
- The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
- Authors: Conti P, Caraffa A, Gallenga CE, Kritas SK, Frydas I, Younes A, Di Emidio P, Tetè G, Pregliasco F, Ronconi G
- Issue date: 2021 Jan-Feb